BRAF NP_004324.2:p.V600D

Known as: Serine/Threonine-Protein Kinase B-raf V600D, BRAF V600D, BRAF NP_004324.2:p.Val600Asp 
A change in the amino acid residue at position 600 in the serine/threonine protein kinase B-raf protein where valine has been replaced by aspartic… (More)
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
Estrogen Receptor β Agonists Differentially Affect the Growth of Human Melanoma Cell Lines
BACKGROUND Cutaneous melanoma is an aggressive malignancy; its incidence is increasing worldwide and its prognosis remains poor… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2014
2014
Dabrafenib in advanced melanoma with BRAF V600E mutation.
Dabrafenib was recently approved by the US Food and Drug Administration for treatment of unresectable or metastatic melanoma with… (More)
Is this relevant?
2013
2013
Activation of an early feedback survival loop involving phospho-ErbB3 is a general response of melanoma cells to RAF/MEK inhibition and is abrogated by anti-ErbB3 antibodies
Treatment of advanced melanoma has been improved with the advent of the BRAF inhibitors. However, a limitation to such treatment… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?